<DOC>
	<DOCNO>NCT00415532</DOCNO>
	<brief_summary>This phase 3b , multi-center , randomize , Standard Care ( SOC ) -controlled , open-label , 52-week treatment study compare romiplostim medical SOC Idiopathic Thrombocytopenia Purpura ( ITP ) , 6-month Safety Follow-up . Patients randomized romiplostim must complete taper discontinuation medical SOC ITP soon medically feasible initiation romiplostim . After completion discontinuation study treatment period , participant transfer another romiplostim study complete 6-month Safety Follow-up period .</brief_summary>
	<brief_title>Romiplostim ( AMG 531 ) Versus Medical Standard Care Immune ( Idiopathic ) Thrombocytopenic Purpura</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Subject â‰¥ 18 year age Subject diagnosis Idiopathic Thrombocytopenia Purpura ( ITP ) accord American Society Hematology ( ASH ) guideline If subject &gt; 60 year age , subject write bone marrow biopsy report confirm diagnosis ITP Subject receive least 1 prior therapy ITP Subject platelet count &lt; 50,000 platelet count fall &lt; 50,000 clinicallyindicated taper discontinuation current ITP therapy Before studyspecific procedure , appropriate write informed consent must obtain Subject splenectomy reason Subject active malignancy Subject history cancer , basal cell carcinoma cervical carcinoma situ , treatment active disease within 5 year Subject known history bone marrow stem cell disorder Subject participate study evaluate polyethylene glycolconjugated recombinant human megakaryocyte growth development factor ( PEGrHuMGDF ) , recombinant human thrombopoietin ( rHuTPO ) , AMG 531 , thrombopoietic protein Subject receive investigational agent procedure Subject currently enrol , complete within last 30 day , another investigational device drug study Subject pregnant breast feeding Subject use adequate contraceptive precaution Subject know sensitivity recombinant E. coliderived product Subject kind disorder compromise ability subject give write informed consent legally acceptable representative Subject kind disorder compromise ability subject comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>splenectomy</keyword>
	<keyword>platelet</keyword>
	<keyword>AMG 531</keyword>
	<keyword>thrombopoietin</keyword>
	<keyword>blood disorder</keyword>
	<keyword>bleed disorder</keyword>
	<keyword>immune thrombocytopenic purpura</keyword>
	<keyword>idiopathic thrombocytopenic purpura</keyword>
	<keyword>immune ( idiopathic ) thrombocytopenic purpura</keyword>
	<keyword>TPO</keyword>
	<keyword>thrombopoietic protein</keyword>
</DOC>